FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2075040688> ?p ?o ?g. }

• W2075040688 abstract "Background: The current treatment strategy in non-small cell lung cancer (NSCLC) adenocarcinoma without epidermal growth factor receptor (EGFR) activating mutation or anaplastic large cell kinase gene (ALK) rearrangement does not differentiate between genotype or smoking status even though resent advances in molecular study in NSCLC. In terms of second line treatment, pemetrexed is considered as a standard treatment in non-squamous NSCLC without EGFR activating mutation or ALK rearrangement. We retrospectively analyzed clinical outcomes of systemic chemotherapy according to molecular characteristics.Methods: Between 2006 and 2012, 131 patients with stage 4 NSCLC adenocarcinoma patients who were enrolled in a Seoul St. Mary's hospital lung cancer multidisciplinary center registry were available for molecular pathology regarding EGFR and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status. Mutations in EGFR (exons 18 to 21) and KRAS (codons 12 and 13) were determined by direct sequencing.Results: Among 131 patients, the frequency of EGFR mutations, KRAS mutations, and no mutations in both genes (double negative [DN]) was 28.2%, 5.3% and 66.4% respectively. Among the DN genotype, 47.1%were never smoker and 37.9% were female. The median progression free survival (PFS) with 1st line platinum based combination chemotherapy was 5.4 months (95% CI: 3.7-7.02) for DN genotype and 7.4 months (95% CI: 5.73-9.06) for EGFR mutation group (p=0.047). According to smoking status, the median PFS with 1st line platinum based combination chemotherapy for never smokers in EGFR mutation group was significantly longer than the DN group (DN-N) (8.4 vs 6.7 months: p=0.018). However among the smokers, no significant difference in median PFS with 1st line chemotherapy between EGFR mutation and DN group (DN-S) were found (6.7 vs 4.6 months: p=0.515). In terms of second line treatment except EGFR tyrosine kinase inhibitors (EGFR-TKI), 64% of DN group and 70.3% of EGFR mutation group received pemetrexed, 21% of DN group and 29.7% of EGFR mutation group received docetaxel. 15.1% of DN group received EGFR-TKIs. The median PFS with second line treatment in DN-N group was 7.7 months (95% CI: 2.1-18.9), 3.1 months (95% CI: 1.4-4.8) and 4.4 months (95% CI: 2.2-6.5) for pemetrexed, docetaxel and EGFR-TKI respectively (p=0.009). However, no significant differences in median PFS between second line treatments was found in DN-S group [3.0 vs 2.8 vs 1.7 months for pemetrexed, docetaxel and EGFR-TKI respectively (p=0.100)]. In EGFR mutation group, no significant difference between pemetrexed and docetaxel was found according to the smoking status.Conclusions: NSCLC without EGFR and K-ras mutation (DN group) had different clinical outcomes according to smoking history. Smoking history could be a useful clinical marker to choose a second-line treatment. However, further genomic study to find a druggable target in this group should be conducted.Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B41.Citation Format: Sook Hee Hong, JinHyoung Kang, Eun kyung Jeon, Seung Joon Kim, Kyo-Young Lee, Sang young Roh. Different clinical outcomes of systemic chemotherapy in non-small cell lung cancer without EGFR and K-ras mutation according to smoking status. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B41." @default.
• W2075040688 created "2016-06-24" @default.
• W2075040688 creator A5012148094 @default.
• W2075040688 creator A5014474281 @default.
• W2075040688 creator A5029589807 @default.
• W2075040688 creator A5033443967 @default.
• W2075040688 creator A5070077415 @default.
• W2075040688 creator A5085772467 @default.
• W2075040688 date "2013-11-01" @default.
• W2075040688 modified "2023-09-22" @default.
• W2075040688 title "Abstract B41: Different clinical outcomes of systemic chemotherapy in non-small cell lung cancer without EGFR and K-ras mutation according to smoking status." @default.
• W2075040688 doi "https://doi.org/10.1158/1535-7163.targ-13-b41" @default.
• W2075040688 hasPublicationYear "2013" @default.
• W2075040688 type Work @default.
• W2075040688 sameAs 2075040688 @default.
• W2075040688 citedByCount "0" @default.
• W2075040688 crossrefType "proceedings-article" @default.
• W2075040688 hasAuthorship W2075040688A5012148094 @default.
• W2075040688 hasAuthorship W2075040688A5014474281 @default.
• W2075040688 hasAuthorship W2075040688A5029589807 @default.
• W2075040688 hasAuthorship W2075040688A5033443967 @default.
• W2075040688 hasAuthorship W2075040688A5070077415 @default.
• W2075040688 hasAuthorship W2075040688A5085772467 @default.
• W2075040688 hasConcept C104317684 @default.
• W2075040688 hasConcept C117643217 @default.
• W2075040688 hasConcept C121608353 @default.
• W2075040688 hasConcept C126322002 @default.
• W2075040688 hasConcept C135763542 @default.
• W2075040688 hasConcept C143998085 @default.
• W2075040688 hasConcept C2776232967 @default.
• W2075040688 hasConcept C2776256026 @default.
• W2075040688 hasConcept C2776694085 @default.
• W2075040688 hasConcept C2777240266 @default.
• W2075040688 hasConcept C2778239845 @default.
• W2075040688 hasConcept C2779438470 @default.
• W2075040688 hasConcept C2781182431 @default.
• W2075040688 hasConcept C2781187634 @default.
• W2075040688 hasConcept C502942594 @default.
• W2075040688 hasConcept C526805850 @default.
• W2075040688 hasConcept C54355233 @default.
• W2075040688 hasConcept C71924100 @default.
• W2075040688 hasConcept C86803240 @default.
• W2075040688 hasConceptScore W2075040688C104317684 @default.
• W2075040688 hasConceptScore W2075040688C117643217 @default.
• W2075040688 hasConceptScore W2075040688C121608353 @default.
• W2075040688 hasConceptScore W2075040688C126322002 @default.
• W2075040688 hasConceptScore W2075040688C135763542 @default.
• W2075040688 hasConceptScore W2075040688C143998085 @default.
• W2075040688 hasConceptScore W2075040688C2776232967 @default.
• W2075040688 hasConceptScore W2075040688C2776256026 @default.
• W2075040688 hasConceptScore W2075040688C2776694085 @default.
• W2075040688 hasConceptScore W2075040688C2777240266 @default.
• W2075040688 hasConceptScore W2075040688C2778239845 @default.
• W2075040688 hasConceptScore W2075040688C2779438470 @default.
• W2075040688 hasConceptScore W2075040688C2781182431 @default.
• W2075040688 hasConceptScore W2075040688C2781187634 @default.
• W2075040688 hasConceptScore W2075040688C502942594 @default.
• W2075040688 hasConceptScore W2075040688C526805850 @default.
• W2075040688 hasConceptScore W2075040688C54355233 @default.
• W2075040688 hasConceptScore W2075040688C71924100 @default.
• W2075040688 hasConceptScore W2075040688C86803240 @default.
• W2075040688 hasLocation W20750406881 @default.
• W2075040688 hasOpenAccess W2075040688 @default.
• W2075040688 hasPrimaryLocation W20750406881 @default.
• W2075040688 hasRelatedWork W1546678577 @default.
• W2075040688 hasRelatedWork W1886333457 @default.
• W2075040688 hasRelatedWork W1965489053 @default.
• W2075040688 hasRelatedWork W2055171582 @default.
• W2075040688 hasRelatedWork W2096755977 @default.
• W2075040688 hasRelatedWork W2416188883 @default.
• W2075040688 hasRelatedWork W2419191343 @default.
• W2075040688 hasRelatedWork W2548145417 @default.
• W2075040688 hasRelatedWork W2557713867 @default.
• W2075040688 hasRelatedWork W2621269107 @default.
• W2075040688 hasRelatedWork W2884784378 @default.
• W2075040688 hasRelatedWork W2947128784 @default.
• W2075040688 hasRelatedWork W2995062130 @default.
• W2075040688 hasRelatedWork W3025656902 @default.
• W2075040688 hasRelatedWork W3031319006 @default.
• W2075040688 hasRelatedWork W3031786605 @default.
• W2075040688 hasRelatedWork W3031856566 @default.
• W2075040688 hasRelatedWork W3092126059 @default.
• W2075040688 hasRelatedWork W3178268844 @default.
• W2075040688 hasRelatedWork W3198346596 @default.
• W2075040688 isParatext "false" @default.
• W2075040688 isRetracted "false" @default.
• W2075040688 magId "2075040688" @default.
• W2075040688 workType "article" @default.